Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of NovoCure Ltd (NASDAQ: NVCR) was $11.81 for the day, up 8.15% from the previous closing price of $10.92. In other words, the price has increased by $8.15 from its previous closing price. On the day, 2.33 million shares were traded. NVCR stock price reached its highest trading level at $11.86 during the session, while it also had its lowest trading level at $10.93.
Ratios:
Our analysis of NVCR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 0.70.
On July 08, 2025, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $30.
Evercore ISI Upgraded its In-line to Outperform on December 02, 2024, whereas the target price for the stock was revised from $18 to $30.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 05 ’25 when Cordova Ashley bought 81,550 shares for $12.22 per share. The transaction valued at 996,859 led to the insider holds 437,569 shares of the business.
Brackmann Christoph bought 20,000 shares of NVCR for $231,800 on Jul 29 ’25. The Chief Financial Officer now owns 141,150 shares after completing the transaction at $11.59 per share. On Jun 03 ’25, another insider, Stafford Kristin, who serves as the Director of the company, sold 999 shares for $17.28 each. As a result, the insider received 17,259 and left with 3,054 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCR now has a Market Capitalization of 1322507264 and an Enterprise Value of 1086947200. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.06 while its Price-to-Book (P/B) ratio in mrq is 3.87. Its current Enterprise Value per Revenue stands at 1.692 whereas that against EBITDA is -6.824.
Stock Price History:
The Beta on a monthly basis for NVCR is 0.75, which has changed by -0.5894737 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, NVCR has reached a high of $34.13, while it has fallen to a 52-week low of $10.70. The 50-Day Moving Average of the stock is -7.79%, while the 200-Day Moving Average is calculated to be -23.46%.
Shares Statistics:
NVCR traded an average of 1.67M shares per day over the past three months and 1776260 shares per day over the past ten days. A total of 111.98M shares are outstanding, with a floating share count of 100.35M. Insiders hold about 10.38% of the company’s shares, while institutions hold 82.92% stake in the company. Shares short for NVCR as of 1763078400 were 5971436 with a Short Ratio of 3.57, compared to 1760486400 on 5242339. Therefore, it implies a Short% of Shares Outstanding of 5971436 and a Short% of Float of 8.42.
Earnings Estimates
The dynamic stock of NovoCure Ltd (NVCR) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.32 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.31 and -$1.5 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$1.48, with 7.0 analysts recommending between -$1.19 and -$1.91.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $178.4M to a low estimate of $158.28M. As of. The current estimate, NovoCure Ltd’s year-ago sales were $161.27MFor the next quarter, 7 analysts are estimating revenue of $168.39M. There is a high estimate of $175.2M for the next quarter, whereas the lowest estimate is $159.37M.
A total of 7 analysts have provided revenue estimates for NVCR’s current fiscal year. The highest revenue estimate was $663M, while the lowest revenue estimate was $639.29M, resulting in an average revenue estimate of $651.21M. In the same quarter a year ago, actual revenue was $605.22MBased on 7 analysts’ estimates, the company’s revenue will be $687.78M in the next fiscal year. The high estimate is $738.6M and the low estimate is $658.79M.
